Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

Merck beat first-quarter estimates on strong demand for Keytruda and newer products. The company also narrowed its 2026 sales guidance and raised its adjusted profit outlook, signaling improved earnings visibility. The update is supportive for shares but is primarily a company-specific earnings and guidance story.

Analysis

Merck beat first-quarter estimates on strong demand for Keytruda and newer products. The company also narrowed its 2026 sales guidance and raised its adjusted profit outlook, signaling improved earnings visibility. The update is supportive for shares but is primarily a company-specific earnings and guidance story.